Aptamer probes for specific recognition of glioblastoma multiforme were generated using a repetitive and broad cell-SELEX-based procedure without negative selection. The 454 sequencing technology was used to monitor SELEX, and bioinformatics tools were used to identify aptamers from high throughput data. A group of aptamers were generated that can bind to target cells specifically with dissociation constants (K d ) in the nanomolar range. Selected aptamers showed high affinity to different types of glioblastoma cell lines, while showing little or no affinity to other cancer cell lines. The aptamers generated in this study have potential use in different applications, such as probes for diagnosis and devices for targeted drug delivery, as well as tools for molecular marker discovery for glioblastomas.

A versatile AFM local oxidation lithography was developed for fabricating clean protein patterns ranging from nanometer to sub-millimeter scale on octadecyltrichlorosilane (OTS) layer of Si (100) wafer. This protein patterning method can generate bio-active protein pattern with a clean background without the need of the anti-fouling the surface or repetitive rinsing. As a model system, lysozyme protein patterns were investigated through their binding reactions with antibodies and aptamers by AFM. Polyclonal anti-lysozyme antibodies and anti-lysozyme aptamer are found to preferentially bind to the lysozyme molecules on the edge of a protein pattern before their binding to the interior ones. It was also demonstrated that the topography of the immobilized protein pattern affects the antibody binding direction. We found that the anti-lysozyme antibodies binding to the edge lysozyme molecules on the half-buried pattern started from the top but the binding on the extruded pattern started from the side because of their different spatial accessibility. In addition, after incubating lysozyme pattern with anti-lysozyme aptamer in buffer solution for enough long time, some fractal-shaped aptamer fibers with 1-6nm high and up to tens of micrometers long were formed by the self-assembling of aptamer molecules on the surface. The aptamer fibers anchor specifically on the edge of protein patterns, which originates from the biospecific recognition between the aptamer and its target protein. Once these edge-bound fibers have formed, they can serve as scaffolds for further assembly processes. We used these aptamer fibers as templates to fabricate palladium and streptavidin nanowires, which anchored on the pattern edges and never cross over or collapse over each other. The aptamer fiber scaffold potentially can lead to an effective means to fabricate and interface nanowires to existing surface patterns.

RNA aptamers are in vitro sequences of RNA that have a high affinity for their target ligand. They have applications in therapeutics, biosensors and molecular machines. While the practical applications of aptamers are increasing, it is important to study their structure and thermodynamics to improve the understanding of these molecular tools. The malachite green aptamer (MGA) provides a model system to study the interactions between aptamer and ligand that do not involve hydrogen bonding between ligand and receptor. While the original application of this aptamer was abandoned, study of the MGA binding pocket revealed an electronegative environment that was harnessed for catalysis. MGA binding also supported the notion that aptamers bind by adaptive binding. Adaptive binding is the ability of molecules to mold themselves around the structure of a ligand thereby incorporating it into their three-dimensional fold. To further expand our understanding of MGA binding and to clarify conflicting reports of affinities, we conducted isothermal calorimetry binding studies. The results reveal that the entropy of complex formation plays a large role in determining binding affinity and ligand specificity. This data combined with previous structural studies show that metal ions are required to stabilize the complexes with non-native ligands, whereas, the complex with the original selection target is stable at low salt and in the absence of divalent metal ions. Next, competitive binding studies using isothermal titration calorimetry were conducted with the aim of understanding the adaptive nature of RNA. The results of these studies reveal that there are limits to the adaptability of the aptamer. Binding of one type of ligand reduces the affinity of the aptamer pocket to a differently shaped ligand, even if this second ligand has a significantly higher affinity. The ability of MGA to change ligand preference based on buffer conditions, and the previously reported catalysis suggested that RNA may have a potential supporting multiple functions in the same molecule. To investigate this possibility we attempted to select an aptamer that supports both ligand binding and catalysis. By conducting both a DNA and RNA selection we hoped to add to the iv collection of DNA and RNA aptamers selected for the same target. There are currently too few of these to determine if any correlation can be made between DNA and RNA sequences that bind the same target. The target of the selection was fluorescein diacetate (FDA), which was chosen with the aim that it would allow the exploration of the inherent potential of the selected aptamer to cleave FDA to fluorescein. The RNA selection proved to be more successful and an attempt was made to characterize the binding of the aptamer to its target fluorescein diacetate. Unfortunately there were complications with the binding assays, but future work is proposed that should address the issues. In order to expand the MGA catalytic repertoire attempts were made to synthesize new ligands that could exploit the catalytic potential of the MGA binding pocket. Unfortunately these attempts were unsuccessful, however further attempts are recommended. The MGA used in this study was transcribed in vitro using T7 RNA polymerase. This process is known to add extra nucleotides to the end of the transcription product. Attempts were made to eliminate the n+1 product by introducing a ribozyme or DNAzyme. These were met with difficulties resulting in low yield, however mass spectrometry revealed that n and n+1 MGA bind to ligand. This, along with secondary structure prediction suggests that MGA n+1 behaves the same as n. Overall, the results presented here provide insights into the capabilities of RNA aptamers with respect to ligand binding and catalysis.

Fibrinogen aggregation is the last step in blood coagulation. Inhibition of fibrinogen aggregation could lead to anticoagulation effects. However, there is no good method for the ready evaluation of fibrinogen coagulation. A commonly used path method is slow and requires an expensive instrument. In this project, we have developed a microplate reader and In evaluating inhibitors of fibrinogen coagulations there is no good method. As an important process in hemostasis, fibrinogen coagulation is often detected by micro-plate reader. In our test of fibrinogen coagulation, we improved the observing and analyzing method by using photograph to see concentration-depended effect of thrombin inhibitors on the coagulation. Three known thrombin inhibitors, AEBSF, APMSF and PMSF, were applied to develop the method for detecting the fibrinogen coagulation. The results showed our method is of accuracy in determination of the amount of fibrin when compared with other types of methods.

Thesis (Ph.D.). / Written for the Dept. of Medicine, Division of Experimental Medicine. Title from title page of PDF (viewed 2008/05/09). Includes bibliographical references.

Universiẗat, Diss., 2002--Frankfurt (Main).

Universiẗat, Diss., 2006--Frankfurt (Main).

The purpose of the study is to purify human growth hormone from the fermentation broth by affinity chromatography. For this purpose, human growth hormone specific oligonucleotide aptamers are selected among an aptamer library / selected oligonucleotides were synthesized and used as ligands. Effect of pH on ligand-human growth hormone complex formation was investigated and the highest complex formation was obtained at pH= 7.0. Human growth hormone is separated from the fermentation broth with 99.8% purity and 41% overall yield. The equilibrium data obtained was described by Langmuir type isotherm where saturation constant (q0) and affinity constant (K) are calculated as 0.338 mg hGH/&micro / mol aptamer and 0.059 mg hGH/ml, respectively. Further, equilibrium data obtained using aptamer affinity column was described by Langmuir type isotherm where saturation constant (q0) and affinity constant (K) are 0.027 mg hGH/&micro / mol aptamer and 1.543 mg hGH/ml, respectively. It is possible that, selected aptamer can be used for purification of bulk amounts of recombinant human growth hormone by using aptamer affinity chromatography.

The World Health Organization estimates that about 10-30% of pharmaceuticals in the world are either substandard or counterfeit. The number is even higher in the developing countries. From a public health perspective, a key contributor to the development and proliferation drug resistant strains of infections, including tuberculosis (TB), malaria and other infections that are leading killers in resource limited settings is poor quality medicines. Most of the main causes are profit driven corruption in many pharmaceutical companies, the poor manufacture and quality control, and/or the inappropriate storage conditions. Poor quality drugs lead to loss of life, create morbidity, strain the financial structure of the health system and lead to long-term drug resistance that affects us all. The current technology for screening poor quality drugs can be divided into 2 categories: the high end, precise and high cost technologies (such as High Performance Liquid Chromatography) and lower cost and qualitative technologies (such as Thin-Layered Chromatography). The high-end methods can give a precise measurement of active pharmaceutical ingredient (API) concentration and the presence of impurities in the tablets, but require trained personnel, advanced machine and lab set up, not suitable for field testing where most of poor quality pharmaceuticals have been found. The lower cost techniques require little training and simple equipment to operate at a relatively inexpensive price, but only gives qualitative results. In addition, most of current methods do not look at the dissolution profile of the tablets simultaneously with the concentration of API. Therefore, we propose to develop an assay that can quantify the concentrations of multiple APIs simultaneously and measure dissolution rates. In order to address current gaps in knowledge, my research proposal has three main parts in the assay development: 1) Development of an fluorescent/luminescent assay for detection of counterfeit/substandard antimalarial using small-molecules-based methods and field testing in Ghana; 2) Development of a fluorescent assay for detection of water-soluble pharmaceuticals using SELEX; and 3) Design a detection platform using microfluidic chips for real time quantification of multiple active pharmaceutical ingredients. For proof-of-concept, an antimalarial drug (artesunate and amodiaquine) and antibacterial antibiotics (sulfamethoxazole and trimethoprim) are selected to demonstrate the probe development and test the chip performance. Overall, the assay will be rapid, robust, portable, inexpensive, multiplexed, quantitative, specific, and sensitive. At a big picture level, emphasizing drug quality and creating robust mechanisms of drug testing will improve health outcomes and enhance treatment efficacy in resource limited settings.

Vários estudos têm apontado a sinalização e os receptores purinérgicos, representados em mamíferos pelos receptores ionotrópicos (P2X1 P2X7) e metabotrópicos (P2Y1,2,4,6, 11,12,14), como um sistema primitivo, envolvido não somente na sinalização neuronal, mas também em muitos outros processos vitais incluindo resposta imune, inflamação, dor, agregação plaquetária e nos processos de diferenciação, proliferação e morte celular, que ocorrem no desenvolvimento e na regeneração tecidual. Condizente com as descrições da literatura, dados do nosso laboratório, baseados na farmacologia dos receptores purinérgicos, sugeriram o envolvimento do subtipo P2Y2 na proliferação e na neurogênese in vitro de células de carcinoma embrionário P19. Tendo em vista a ausência de agonistas e antagonistas específicos para a maioria dos subtipos de receptores purinérgicos, o que vem dificultando a elucidação das funções exatas desses receptores em processos fisiológicos e patológicos, optamos para o screening de uma biblioteca combinatória de oligonucleotídeos para a identificação de ligantes de alta afinidade e especificidade para o receptor P2Y2 (procedimento de SELEX, Evolução Sistemática de Ligantes por Enriquecimento Exponencial). Essa abordagem envolve passos reiterativos de seleção in vitro de moléculas de RNA, estabilizadas por substituição do grupo 2´OH das pirimidinas por um átomo de flúor, que possuem afinidade pelo receptor, até que a mistura de RNAs, originalmente de 1013 diferentes seqüências que adotam uma gama de estruturas secundárias e terciárias, esteja purificada para uma população homogênea de ligantes de alta afinidade pelo receptor P2Y2. O processo envolve a transcrição in vitro da biblioteca de DNA para RNA, a apresentação desta ao alvo, a eluição dos ligantes específicos, denominados aptâmeros, e a regeneração da biblioteca de DNA por RT-PCR, a qual, após uma reação de transcrição in vitro, gera a mistura de RNAs para o próximo ciclo de seleção. Neste trabalho, nós utilizamos como alvo o receptor P2Y2 recombinante humano expresso na linhagem de células de astroglioma humano 1321N1. Ao final de nove ciclos de SELEX, nós isolamos 46 sequências que foram agrupadas em três classes estruturais, de acordo com a presença de regiões consensos. A mistura destas moléculas se ligou ao receptor P2Y2 humano com uma constante de dissociação de 164 nM. Um dos clones isolados, o aptâmero B7, se ligou preferencialmente ao receptor P2Y2 (Kd 184 nM), em relação aos receptores P2Y1 e P2Y4 recombinantes expressos em células 1321N1. A interação deste aptâmero não foi dependente da espécie, uma vez que ele foi capaz de se ligar tanto ao receptor P2Y2 de origem humana como murina. A atividade biológica do aptâmero foi avaliada em células P19 (sabidamente expressando receptores P2Y2 endógenos), na qual a proteção do ATP contra a apoptose, provavelmente interagindo com o receptor P2Y2, foi anulada na presença deste aptâmero em uma concentração mil vezes menor do que a do ATP. Além de confirmar a viabilidade da técnica SELEX para identificar ligantes subtipos-específicos dos receptores purinérgicos, o aptâmero anti-P2Y2 serve como ferramenta fundamental para definir demais funções fisiológicas deste receptor. Passos de otimização das suas propriedades como ligante e biodisponibilidade tornarão este aptâmero um composto de alta relevância farmacêutica. / Many published studies have focused on purinergic signaling and receptors, represented by ionotropic (P2X1 P2X7) and metabotropic (P2Y1,2,4,6,11,12,14) subtypes as a universal system which is not only involved in neuronal signaling, but also in various other vital processes including immune response, inflammation, platelet aggregation as well as differentiation, proliferation and cell death occurring during development and tissue regeneration. In agreement with other published reports, results of our laboratory based on overlapping purinergic receptor pharmacology suggest the participation of the P2Y2 subtype in proliferation and in vitro neurogenesis of P19 embryonal carcinoma cells. In view of the lack of availability of specific agonists and antagonists for most purinergic receptors making the elucidation of exact functions of these receptors in their cellular context almost impossible, we used a combinatorial oligonucleotide library approach, denominated SELEX (Systematic Evolution of Ligands by Exponential Enrichment) for the development of high-affinity and specificity ligands for the P2Y2 receptor. This approach is based on re-iterative steps of in vitro selection of 2´-fluoro-pyrimidine-modified RNA molecules for receptor-binding affinity from an RNA pool containing 1013 different sequences and secondary and tertiary structures until this pool is purified to a homogeneous population of ligands with high affinity to the P2Y2 receptor. The combinatorial DNA library is in vitro transcribed into RNA followed by target presentation of the RNA library and elution of the target-binders, denominated aptamers, and RT-PCR amplification in order to restore the DNA library used for in vitro transcription for next SELEX cycle. Following nine SELEX cycles using 1321N1 human astroglial cells expressing recombinant human P2Y2 receptors as target, we isolated 46 aptamer sequences which, based on consensus sequence motifs, were grouped in three structural groups. The mixture of the isolated sequences bound themselves to human P2Y2 receptors with a dissociation constant (Kd) of 164 nM. One of the isolated clones, the aptamer denominated B7, bound itself to P2Y2 receptors in preference to P2Y1 and P2Y4 recombinant receptors expressed in 1321N1 cells. The binding activity of the aptamer was not limited to P2Y2 receptors of human origin, as the aptamer also interacted with mouse P2Y2 receptors. The capability of the aptamer of affecting the biological activity of P2Y2 receptors was verified in P19 cells in which ATP-induced protection against apoptosis, mediated by P2Y2 receptors, was abolished in the presence of the aptamer. In addition to providing a proof of principle for the feasibility of developing purinergic subtype-specific ligands by using the SELEX technique, the anti-P2Y aptamer provides a fundamental tool for gaining insights of physiological functions of this receptor in various cellular contexts. Moreover, steps of optimization of receptor binding properties and aptamer half-life in vivo will turn this aptamer into a compound of high pharmaceutical relevance.